Neuroscientific Biopharmaceuticals Ltd has released a press release.
EmtinB Positive Results in MS
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Final Report received for Glaucoma Study
- Positive Results in MS Study
- Positive Results in Glaucoma Pig Model
- Additional US Patent granted
- CVN Model Indicates Neuroprotective Properties of EmtinB
Later from Neuroscientific Biopharmaceuticals
- Full Report from Multiple Sclerosis Study
- Updated Appendix 4C
- Appendix 4E and Annual Report
- Strategic Placement to AlphaSwiss Partners
- NSB to investigate treatment for post-COVID Fibrosis
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals